Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Trevena in a report on Thursday, November 14th.

Trevena Price Performance

TRVN stock opened at $1.69 on Thursday. The firm has a 50 day moving average of $1.70 and a two-hundred day moving average of $3.02. Trevena has a 12 month low of $1.13 and a 12 month high of $17.50.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The company had revenue of $0.28 million for the quarter. Research analysts anticipate that Trevena will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.